Project Grant RF1AG079176
- This Project Grant award of $431,750 from the National Institute on Aging's Aging Research program (CFDA 93.866) will support research to investigate the interaction between biological sex and APOE genotype in modulating Alzheimer's disease (AD) risk. The research will leverage human induced pluripotent stem cell lines with various APOE genotypes and sex chromosome complements to examine how APOE and sex influence amyloid-beta processing, tau hyperphosphorylation, and transcriptional changes...
- Federal Grant Award Summary The University of Miami's Office of Research Administration received a $3.23 million Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) effective March 1, 2026 through February 28, 2031. This award supports integrative research analyzing the X chromosome's contribution to Alzheimer's disease (AD) risk and progression. The project leverages large-scale population-based genetic, epigenetic, and multi-omics datasets to...
- Federal Project Grant Summary Yale University received a $1,624,822 project grant from the National Institute on Aging under the Aging Research program (CFDA 93.866), awarded May 15, 2025, with completion targeted for February 28, 2030. The grant funds a multimodal neuroimaging research study investigating sex-based contributors to Alzheimer's disease vulnerability. The project delivers two primary research products: (1) a prospective cohort study examining sex differences in functional brain...
- This five-year, $813,838 project grant from the National Institute of Allergy and Infectious Diseases will fund research into the genetic and hormonal mechanisms underlying sex differences in tuberculosis (TB) and TB-HIV coinfection. The Johns Hopkins University will investigate how X chromosome complement and sex steroid hormones impact TB pathogenesis using cellular models, animal studies, and human samples. Researchers will utilize a novel four core genotype mouse model to differentiate the...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $462,923 to Albany Medical College to develop new mouse models of andropause (age-related decline in male sex hormones) for Alzheimer's disease and related dementia (ADRD) research. The primary goals are to: Determine the natural time course of endocrine aging in wild-type mice and mouse models of ADRD (Aim 1). Model endocrine aging in male mice via gonadectomy and gradual androgen...
- The National Institute on Aging (NIA) awarded a $3,281,385 Project Grant under the Aging Research federal grant program (CFDA 93.866) to the University of California, San Diego (UCSD) to leverage 30 years of Alzheimer's disease clinical trials data. The goal is to examine the role of specific patient phenotypes, such as sex/gender, APOE4 status, and polygenic hazard scores, on response to drug or lifestyle interventions. The project will analyze data from 14,602 participants across multiple...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded a $3.43 million Project Grant to The Regents of the University of California, San Francisco on September 15, 2025, under the Aging Research program (CFDA 93.866). This four-year award, scheduled for completion on August 31, 2029, funds a comprehensive research initiative investigating biological drivers of sex differences in frontotemporal dementia (FTD). The research will leverage two deeply phenotyped,...
- The Washington University in St. Louis, Office of Sponsored Research Services Division, received a $2,133,060 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866). The grant will support research to investigate the sex-dependent effects of stress on the accumulation of amyloid-beta (Aβ) and tau proteins, which are hallmarks of Alzheimer's disease pathology. The study aims to elucidate the signaling pathways that mediate the differential...
- Federal Project Grant Award Summary Northwestern University's Sponsored Research Division received $148,050 from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to conduct a research project investigating sex-specific hypothalamic pathology and immune infiltration in Alzheimer's disease (AD). The award, issued on September 27, 2025, with a completion date of May 31, 2028, funds biomedical research directed toward understanding the mechanisms underlying sex...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded Columbia University's Health Sciences Division a $244,023 Project Grant effective August 1, 2025, through July 31, 2028, under the Aging Research program (CFDA 93.866). This research project investigates the social mechanisms underlying sex differences in Alzheimer's Disease (AD), with particular focus on how societal barriers experienced by women—especially Black women—contribute to disparate cognitive health outcomes and...
SEX DIFFERENCES IN EPIGENETIC PARENT-OF-X ORIGIN AND ALZHEIMER'S DISEASE - PROJECT SUMMARY/ABSTRACT BIOLOGIC SEX INFLUENCES ALZHEIMER'S DISEASE (AD). A MAJOR SOURCE OF BIOLOGIC DIFFERENCE BETWEEN THE SEXES IS THAT FEMALES HAVE TWO X CHROMOSOMES AND MALES HAVE ONE. THE SEX-SPECIFIC ROLE OF THE X CHROMOSOME IN INFLUENCING AD IS LARGELY UNKNOWN. THIS GRANT FOCUSES ON X-CHROMOSOME-DERIVED MECHANISMS OF SEX DIFFERENCE USING MOUSE MODELS AND PRIMARY NEURONS COMBINED WITH GENETIC AND EPIGENETIC TOOLS FOR MOLECULAR DISSECTION. UNDERSTANDING THIS UNDERSTUDIED AREA MAY REVEAL NEW X-BASED PATHWAYS THAT COULD ULTIMATELY BENEFIT BOTH SEXES. SEX DIFFERENCES IN AD REVEAL DIFFERING VULNERABILITIES IN MEN AND WOMEN. IN BRIEF, MALE SEX IS A RISK FACTOR FOR RAPID PROGRESSION TO DEATH IN AD. THESE FINDINGS SUPPORT THE FACT THAT MANY MORE WOMEN HAVE AD, DUE IN PART TO THEIR LONGEVITY AND ALSO TO THEIR INCREASED RISK OR INCIDENCE IN OLDER AGE - WHICH TOGETHER CONTRIBUTES TO A HIGHER LIFETIME RISK OF AD IN WOMEN. USING GENETIC MODELS OF SEX BIOLOGY, WE FOUND THAT THE SECOND X CHROMOSOME COUNTERS MORTALITY, DEFICITS AND TOXICITY RELATED TO HAPP/ASS IN BOTH MALE AND FEMALE MICE AND PRIMARY NEURONS. SINCE ONE X INACTIVATES IN FEMALES, X DOSE IS LARGELY SIMILAR BETWEEN THE SEXES. THIS RAISES A KEY QUESTION: WHY WOULD HAVING TWO X'S CONFER ADVANTAGE TO AD-RELATED MEASURES? EACH FEMALE CELL HARBORS TWO X CHROMOSOMES BUT ONE IS SILENCED THROUGH RANDOM X CHROMOSOME INACTIVATION (XCI). XCI INDEPENDENTLY SILENCES ONE X CHROMOSOME IN EVERY XX CELL TO ACHIEVE DOSAGE COMPENSATION OF X EXPRESSION BETWEEN MALE AND FEMALE CELLS. THUS, XX FEMALES ARE MOSAICS WITH THEIR ACTIVE X CHROMOSOMES BEING EITHER MATERNALLY-DERIVED (XM) OR PATERNALLY-DERIVED (XP), WHEREAS MALES HAVE A SINGLE MATERNAL X (XM). A POTENTIAL BENEFIT OF HAVING TWO X'S IS THAT THE DIVERSE COMBINATION OF MATERNAL AND PATERNAL X CHROMOSOMES (XM+XP) COULD BUFFER DELETERIOUS CELLULAR PROCESS RELATED TO AD. WE HYPOTHESIZE THAT XM CONTRIBUTES FUNCTIONAL DEFICITS TO AD PATHOPHYSIOLOGY IN MALES THROUGH EPIGENETIC MECHANISMS - AND THAT MOSAICISM OF THE X (XM+XP) IN FEMALES BUFFERS DEFICITS. SINCE XM AND XP ARE GENETICALLY IDENTICAL IN OUR MODELS, ANY DIFFERENCES BETWEEN THE TWO ARE ATTRIBUTED TO EPIGENETICS. WE WILL PURSUE TWO AIMS: 1. IN AIM 1, WE WILL EXAMINE EPIGENETIC, PARENT-OF-X ORIGIN AND ITS MODULATION OF NEURAL VULNERABILITY TO AD- RELATED DEFICITS IN XX COMPARED TO XY MICE AND CELLS. WE HYPOTHESIZE THAT THE MATERNAL X CHROMOSOME WORSENS NEURAL VULNERABILITY TO AD. 2. IN AIM 2, WE WILL DEFINE HOW SILENCING, OR IMPRINTING, OF THE MATERNAL X CHROMOSOME IMPACTS EACH SEX IN AD-RELATED TOXICITY. WE HYPOTHESIZE THAT THE MATERNAL X SILENCES SELECT GENES IN A CELL-TYPE SPECIFIC MANNER - AND THIS CONTRIBUTES TO SEX-SPECIFIC NEURAL VULNERABILITY. ANSWERS TO OUR QUESTIONS IN XX COMPARED TO XY MICE AND CELLS WILL FUNDAMENTALLY ADVANCE MECHANISTIC UNDERSTANDING OF HOW THE X CHROMOSOME CONTRIBUTES TO SEX DIFFERENCE IN AD, AND WILL LIKELY PAVE X-BASED PATHS TOWARD URGENTLY NEEDED TREATMENTS IN AD, PERSONALIZED FOR MEN, WOMEN, OR BOTH.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 1/27/26 | ||
| Not listed | $1.7m | 7/19/22 | ||
| Not listed | $1.7m | 7/19/22 |